Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Humira adalimumab: Phase III; marketed for rheumatoid arthritis (RA)

October 13, 2003 7:00 AM UTC

ABT started a double-blind, placebo-controlled U.S. Phase III study of Humira in an undisclosed number of patients with psoriatic arthritis that have had inadequate response to disease-modifying anti-...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article